Krsnaa Diagnostics Limited

rs,

GOOD ... ® Date: 09th November, 2022 BSE Ltd. Corporate Service Department pt Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip ID: KRSNAA Scrip Code: 543328 Dear Sir/Madam, The Nationa

18.7%

rovider Q2 FY2023 Performance 2 Core Business Continues to Grow In Q2 FY23, Core Revenue up by 18.7% Y-o-Y despite high base in Q2 FY22 due to second wave of Covid-19 EBITDA margins remained strong a

25.2%

-o-Y despite high base in Q2 FY22 due to second wave of Covid-19 EBITDA margins remained strong at 25.2% and improvement is expected in upcoming quarters with operationalization of new centres Total Reve

29.9%

2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 3 3 EBITDA2 Profit After Tax 324 29.9% 310 283 25.1% 25.2% 125 11.6% 142 153 12.6% 12.5% Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1

25.1%

Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 3 3 EBITDA2 Profit After Tax 324 29.9% 310 283 25.1% 25.2% 125 11.6% 142 153 12.6% 12.5% Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 N

11.6%

2 FY22 Q1 FY23 Q2 FY23 3 3 EBITDA2 Profit After Tax 324 29.9% 310 283 25.1% 25.2% 125 11.6% 142 153 12.6% 12.5% Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Notes: 1. Covid-19

12.6%

Q2 FY23 3 3 EBITDA2 Profit After Tax 324 29.9% 310 283 25.1% 25.2% 125 11.6% 142 153 12.6% 12.5% Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Notes: 1. Covid-19 Business is inclu

12.5%

3 3 EBITDA2 Profit After Tax 324 29.9% 310 283 25.1% 25.2% 125 11.6% 142 153 12.6% 12.5% Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Notes: 1. Covid-19 Business is including Co

14.7%

excluding CSR and ESOP expenses 3 Core Business Continues to Grow In H1 FY23, Core Revenue up by 14.7% Y-o-Y despite high base in H1 FY22 EBITDA margins at 25.1% and improvement is expected in upcomin

30.9%

oY H1 FY22 H1 FY23 H1 FY22 H1 FY23 H1 FY22 6 H1 FY23 2,051 EBITDA2 Profit After Tax 745 30.9% 593 25.1% 341 14.2% 296 12.5% H1 FY22 H1 FY23 H1 FY22 H1 FY23 Notes: 1. Covid-19 Busine

14.2%

FY22 H1 FY23 H1 FY22 6 H1 FY23 2,051 EBITDA2 Profit After Tax 745 30.9% 593 25.1% 341 14.2% 296 12.5% H1 FY22 H1 FY23 H1 FY22 H1 FY23 Notes: 1. Covid-19 Business is including Covid al

88%

f 30 including 1 Referral Laboratory and 95 Collection Centers. This amounts to the completion of 88% of the project as of date. Considering the rising demand for diagnostics services and to cater to

“This amounts to the completion of 88% of the project as of date.”

“Considering the rising demand for diagnostics services and to cater to the remotest parts of the country, Krsnaa Diagnostics has entered selected markets through the franchise and in addition plan to launch 600 collection centers across India, providing services at attractive prices.”

“Maturity is on the basis of the project start date 3.”

“29 Krsnaa Diagnostics Edge One of the Fastest Growing Diagnostics Service Provider in the country Extensive Geographic Footprint Strong Brand Equity Scalable and Agile Business Model Disruptive Pricing Stakeholder Value Creation Total Centre count increased at a CAGR of 32% from 682 in FY18 to 2050+ in FY21 Centres across India with presence in 14 States.”

Notes

7

Regional Chains due to

1

Entry Limitations

1

Note

1

For further information please contact

1

Notes

1. Covid-19 Business is including Covid allied tests 2. EBITDA is excluding CSR and ESOP expenses 3 Core Business Continues to Grow In H1 FY23, Core Revenue up by 14.7% Y-o-Y despite high base in H1 FY22 EBITDA margins at 25.1% and improvement is expected in upcoming quarters with operationalization of new centres Total Revenue 2,407 2,358 Core Business Revenue +14.7% YoY 2,352 Covid-19 Revenue1 Rs. Million 356 (98.4)% YoY H1 FY22 H1 FY23 H1 FY22 H1 FY23 H1 FY22 6 H1 FY23 2,051 EBITDA2 Profit After Tax 745 30.9% 593 25.1% 341 14.2% 296 12.5% H1 FY22 H1 FY23 H1 FY22 H1 FY23

Notes

1. Covid-19 Business is including Covid allied tests 2. EBITDA is excluding CSR and ESOP expenses 4 Management Perspectives Commenting on the business, Ms. Pallavi Bhatevara, Managing Director, said: “Krsnaa Diagnostics has always been at the forefront when it comes to serving the healthcare needs of our society. Today the company is the largest premium quality integrated diagnostics service provider in India with 2,000+ locations with accessible and affordable rates. In line with our growth strategy, Krsnaa Diagnostic has operationalized 10 pathology labs out of 24 and 126 collection centers out of 190 in Himachal Pradesh. In the state of Punjab, the company has operationalized 20 CT Scanners out of 25, 5 MRI Machines out of 6, 18 Pathology Labs out of 30 including 1 Referral Laboratory and 95 Collection Centers. This amounts to the completion of 88% of the project as of date. Considering the rising demand for diagnostics services and to cater to the remotest parts of the country, Krs

Notes

1. Covid-19 Business is including Covid allied tests 2. 3. Financial results of the Company are best monitored on a trailing 12-month basis, as there is material seasonality in business and quarterly performances are likely to be impacted by such seasonal factors. EBITDA is excluding CSR and ESOP expense EBIT including Other Income 6 Well Capitalized Balance Sheet to Fund the Growth (Rs. Million) Long Term Debt Short Term Debt Total Debt Cash & Cash Equivalents Net Debt / (Net Cash) Total Equity Cash Flow From Operating Activities Before Tax FY18 FY19 FY20 FY21 FY22 H1FY22 H1FY23 556 452 1,008 219 789 806 351 937 772 1,709 1,281 428 1,890 1,400 1,112 2,512 1,379 1,133 2,014 1,680 638 2,318 1,624 694 2,319 331 79 410 362 177 539 300 326 626 3,480 3,841 2,839 (3,070) (3,302) (2,213) 6,868 6,449 7,061 681 516 1,102 1,351 717 (19) Receivables Days • • • Krsnaa has built a strong cash flow generating business model backed by strong cash flow conversion cycle and efficient working capital ma

Regional Chains due to

▪ ▪ Krsnaa’s expertise and scale of business Access to high-cost radiology machines at relatively lower prices

Entry Limitations

▪ High capex, low opex model is tough to enter ▪ Disruptive pricing model makes it tough for competition to compete ▪ Larger chains focused on pathology tests Note: Peer information is based on publicly available information as on 31st March, 2022 and for representative purposes only 13 High Quality Diagnostic Services at Disruptive Prices Krsnaa Offers Tests at 60-80% Lower than Market Rates Segment Test Player 1 Player 2 Player 3 Krsnaa RDL RDL PTH PTH PTH PTH PTH PTH CT Brain MRI Brain CBC Blood Sugar Thyroid Vitamin D Vitamin B12 HbA1C 4,500 8,000 250 85 500 1,500 1,000 550 4,500 8,250 250 80 550 1,250 1,100 440 3,500 7,000 200 70 550 1,450 1,300 400 973 2,209 146 26 216 595 243 141 % from min price (72)% (68)% (27)% (63)% (57)% (52)% (76)% (65)% high Krsnaa Diagnostics diagnostics services at disruptive prices offers quality Well placed to withstand any industry price caps as well pricing pressure on tests Cost Disruption… Leading to a Virtuous Cycle.. Low fixed cost of operations

Notes

1. 2. Maturity is on the basis of the project start date 3. Return on Capital Employed calculated as (EBIT including Other Income / Gross Block) 23 Fully Geared to Disrupt the Growing Retail Market Retail Market Expansion Strategy Pathology through Krsnaa Business Associates Wellness 5 key wellness and 5 key illness package Launch of specialized tests- Genomics Expansion in Retail Market Hospital Lab Management Tele reporting support – For key alliances Franchisee Model Pick-Up-Points (Nursing Homes, Hospitals, small and mid- sized Laboratories, SIS, HLM, DOL) Awareness (Camps and Corporates, Wellness & Illness Packages) PACE Collection Centre Network and Franchisee CCs (Krsnaa Business Associates- KBA) Essential (Home) Collection Services 24 Expanding B2C Pathology Service Offerings Capitalizing on the extensive infrastructure of Pathology Diagnostics and extending it to end consumers 749 Pathology Centres 72 677 Processing Labs Collection Centres ▪ Expanding B2C pathology diagnostic